Charlie Gard’s Parents Withdraw Legal Bid, Slam Court

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
228
Charlie Gard’s Parents Withdraw Legal Bid, Slam Court for ‘Time Wasted’



The parents of baby Charlie Gard have withdrawn their legal bid to bring their son to the United States for treatment, slamming doctors and the courts for “time wasted”.

Speaking in court, the baby’s mother claimed her son was “not brain dead” and could have lived a normal life if he had been released for treatment abroad, which was prevented by doctors, lawyers and bureaucrats.

Lawyer Grant Armstrong revealed that the parents – Chris Gard and Connie Yates – were withdrawing their appeal after seeing Charlie’s latest scans, saying that treatment should now end. The court was due to make a decision on Tuesday, but proceedings will no longer continue.

Mr Armstrong told Mr Justice Francis that “time had run out” for the 11-month-old baby, and the couple cried at London’s High Court as the announcement was made.

Speaking outside the court, father Chris Gard said: “Put simply, this is about a sweet, gorgeous, innocent little boy, born with a rare disease, who had a real, genuine chance of life and a family who love him so very dearly – and that’s why we fought so hard for him.

“We are truly devastated,
to say the least, that following the most recent MRI scan of Charlie’s muscles, as requested in a recent MDT meeting with Dr Hirano, as Charlie’s devoted and loving parents we have decided that it is no longer in Charlie’s best interests to pursue treatment and we will let our son go and be with the angels.

“The American and Italian teams were still willing to treat Charlie,” he said, “but there is one simple reason why treatment cannot now go ahead – and that is time. A whole lot of time has been wasted.”

The parents had been fighting court rulings saying their son’s life support should be withdrawn so he could “die with dignity” for months.

“We are now in July,” noted Mr Gard. “Our poor boy has been left to lie in hospital for months, without any treatment, while lengthy court battles have been fought.

“Tragically, having had Charlie’s medical notes reviewed by independent experts, we now know had Charlie been given the treatment sooner he would have had the potential to be a normal, healthy little boy,” he said.

“Charlie has been left with his illness to deteriorate devastatingly to the point of no return.”

Mr Gard said their long fight had “never been about ‘the parents know best’. All we wanted to do was take Charlie from one world-renowned hospital to another world-renowned hospital, in an attempt to save his life, and to be treated by the world leader in mitochondrial disease.

“We will have to live with ‘What Ifs’ for the rest of our lives. Despite the way our son has been spoken about from time to time – as if he is not worthy of a chance at life – our son is an absolute warrior and we could not be more proud of him and we will miss him terribly.

“His body, heart, and soul may soon be gone, but his spirit will live on for eternity and he will make a difference to people’s lives for years to come. We will make sure of that.

The results of new scans showed the baby’s condition was such that further treatment could cause suffering.

Doctors from the Vatican children’s hospital and American neuroscientist Dr Michio Hirano had disagreed with Great Ormond Street and the British courts, arguing that experimental therapy could save the child’s life and offering to treat him.

The European Court of Human Rights was described as a “death panel” after denying the parents the opportunity to appeal to privately fund their final attempts to save their son.

Charlie received high-profile support from U.S. President Donald Trump, Vice President Mike Pence, and Pope Francis.

According to the Evening Standard, people outside the court – mainly women and children – filled the road chanting: “Trump, the Pope, they all have hope!” and, “We love you Charlie, We do, Oh Charlie we love you!”

Last week, the U.S. Congress granted Charlie permanent residency in the U.S. so he could go quickly to America for treatment.

The bill was introduced by Rep. Jaime Herrera Beutler (R-WA) who was told by doctors that her unborn child could not survive.

She fought to save her, and the baby girl became the first in the world to survive after being born without both kidneys.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Consumer365 Highlights Happy Head's Personalized Hair Solutions

Updated Category News Views 1

Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...

Continue Reading
GEEKOM A5 2027: Mini PC Built to Boost Your Game

Updated Category News Views 2

GEEKOM Raises the Bar with A5 2027 Build Every once in a blue moon, a piece of tech pricks up my ears and this time it's the GEEKOM A5 2027 Edition. Released on September 7, 2026, this contraption's not just joining the ranks—it's looking to redefine them. It's geared for the real-world junkie who’s raking through browser tabs, dropping into video meetings, and making...

Continue Reading
CME Group Smashes FX Open Interest Record Again

Updated Category News Views 4

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

Continue Reading
Moonlock: Award-Winning Design Elevates Cybersecurity's Importance

Updated Category News Views 2

Design Excellence Meets Cybersecurity There's a new sheriff in town when it comes to cybersecurity design, and its name is Moonlock. MacPaw's antivirus and protection app pulled off a coup by bagging the 2026 Red Dot Award in the Interface & User Experience Design category. It's a big deal in the cybersecurity realm, where functionality often overshadows finesse. But...

Continue Reading
Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 2

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Jixingfeng Advances Smart Manufacturing for Socks Market

Updated Category News Views 3

Socks Evolve: From Feet Covers to Tech Gear Once upon a time, socks were merely foot covers, destined to vanish beneath pants and shoes. But not anymore. In the bustling halls of the sock world, Jixingfeng built up a robust repertoire of producing high-performance hosiery for a modern market that demands more than just warmth. They’ve turned socks into a tech-infused...

Continue Reading
Europe's Largest Carbon Capture Facility Launches

Updated Category News Views 2

A New Chapter in Industrial Decarbonization Today's not just your average ribbon-cutting ceremony; it's a landmark turn in our journey toward a cleaner Europe. Yara's Sluiskil plant in the Netherlands just fired up Europe's biggest carbon capture facility, marking a crucial pivot point in industrial decarbonization. We're talking about capturing a staggering 800,000 tons...

Continue Reading
Lida Group Expands Global Modular Construction Services

Updated Category News Views 5

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Continue Reading
Innventure Faces Class Action: SEC Whistleblowers Invited

Updated Category News Views 1

When Fiction Meets the Stock Market Here's a wild twist in the investment world: Innventure, Inc. (NASDAQ: INV) found itself in hot water, as its stock took a nosedive, plunging 55% on August 14, 2026. Imagine seeing your investments crumble just like that. What lit this fire? The decision to yank their DarkNX project from 2026 expectations and hit pause on their revenue...

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the P/E Ratio of IDEXX Laboratories for Investors

Updated Category News Views 154

Understanding the P/E Ratio of IDEXX Laboratories IDEXX Laboratories Inc. (NASDAQ: IDXX) is currently trading at $766.68, reflecting a modest rise of 1.93%. Over the last month, there has been an impressive increase of 20.86%, and a remarkable jump of 81.78% over the past year. Such performance instills a sense of optimism among long-term shareholders, but it also raises...

Continue Reading
Current Market Dynamics of CRISPR Therapeutics: Insights and Trends

Updated Category News Views 158

Understanding CRISPR Therapeutics' Market Position CRISPR Therapeutics is on the radar of investors, with recent reports indicating that its short interest as a percentage of float has decreased by 5.29%. As it stands, there are approximately 22.07 million shares sold short, representing 27.41% of all regular shares available for trading. This percentage suggests a...

Continue Reading
Arixa Capital Achieves Record Loan Originations with Team Growth

Updated Category News Views 127

Arixa Capital Achieves Impressive Loan Originations Record Arixa Capital, a prominent player in the private real estate lending arena, has reached an exciting milestone by surpassing $440 million in loan originations during Q3 2024. This accomplishment not only emphasizes Arixa's stronghold in the market but also highlights its commitment to offering flexible financing...

Continue Reading
February New-Vehicle Sales: A Mixed Bag for Auto Enthusiasts

Updated Category News Views 232

February Sales Show Flicker of Hope Amid Challenges This month, the automotive market reveals a glimmer of recovery, albeit a tepid one. February's new-vehicle sales pace is projected to land at about 15.6 million, a modest boost from January’s 14.9 million but still trailing last February’s 16.0 million. That's a mixed bag if I've ever seen one. Sales volume for the...

Continue Reading
GA Telesis Expands Offerings with Landing Gear Acquisition

Updated Category News Views 147

GA Telesis Acquires AAR's Landing Gear Overhaul Business GA Telesis, LLC, a renowned provider of integrated aviation services, has embarked on an exciting journey that will redefine its service offerings. The company has officially signed an agreement to acquire AAR CORP.'s Landing Gear Overhaul business along with its Wheels & Brakes business unit. This strategic move...

Continue Reading